E
Adicet Bio, Inc. ACET
$6.47 -$0.26-3.86% NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
Corporate Info
Phone Number
650 503 9095
Address
131 Dartmouth Street
3rd Floor
Boston, MA 02116
Country
United States
Year Founded
2014
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
Business Description
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.